Last reviewed · How we verify

LivaloVA — Competitive Intelligence Brief

LivaloVA (LivaloVA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

phase 3 HMG-CoA reductase inhibitor (statin) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

LivaloVA (LivaloVA) — JW Pharmaceutical. LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LivaloVA TARGET LivaloVA JW Pharmaceutical phase 3 HMG-CoA reductase inhibitor (statin) HMG-CoA reductase
Crestor rosuvastatin AstraZeneca marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 2003-01-01
Lipitor atorvastatin Pfizer Inc. marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 1996-12-17
Lescol FLUVASTATIN Novartis marketed HMG-CoA Reductase Inhibitor HMG-CoA reductase 1993-01-01
FLUVASTATIN SODIUM FLUVASTATIN SODIUM marketed HMG-CoA reductase 1993-01-01
Amlodipine + Simvastatin Amlodipine + Simvastatin University of Pavia marketed Calcium channel blocker + HMG-CoA reductase inhibitor (statin) L-type voltage-gated calcium channel; HMG-CoA reductase
simvastatin and ezetimibe simvastatin and ezetimibe UMC Utrecht marketed Statin and cholesterol absorption inhibitor combination HMG-CoA reductase and NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (HMG-CoA reductase inhibitor (statin) class)

  1. Organon and Co · 7 drugs in this class
  2. Kuhnil Pharmaceutical Co., Ltd. · 3 drugs in this class
  3. Wenzhou Medical University · 2 drugs in this class
  4. Amgen · 2 drugs in this class
  5. Beijing Tiantan Hospital · 2 drugs in this class
  6. Seoul National University Hospital · 2 drugs in this class
  7. JW Pharmaceutical · 2 drugs in this class
  8. AstraZeneca · 2 drugs in this class
  9. Korea University Anam Hospital · 2 drugs in this class
  10. Gachon University Gil Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LivaloVA — Competitive Intelligence Brief. https://druglandscape.com/ci/livalova. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: